These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 23200625

  • 1. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
    Allen A, Davis A, Hardes K, Tombs L, Kempsford R.
    Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
    Chen X, Zheng X, Jiang J, Hu P, Wu K, Zhuang L, Liu L, Du X, Kempsford R, Allen A.
    Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
    [Abstract] [Full Text] [Related]

  • 3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 4. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
    Nakahara N, Wakamatsu A, Kempsford R, Allen A, Yamada M, Nohda S, Hirama T.
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):660-71. PubMed ID: 23735179
    [Abstract] [Full Text] [Related]

  • 5. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
    Kempsford R, Allen A, Bareille P, Hamilton M, Cheesbrough A.
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):2-11. PubMed ID: 27127998
    [Abstract] [Full Text] [Related]

  • 6. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
    Mehta R, Hardes K, Kelleher D, Preece A, Tombs L, Brealey N.
    Clin Ther; 2014 Jul 01; 36(7):1016-1027.e2. PubMed ID: 24947493
    [Abstract] [Full Text] [Related]

  • 7. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.
    Respir Med; 2013 Apr 01; 107(4):550-9. PubMed ID: 23332861
    [Abstract] [Full Text] [Related]

  • 8. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C.
    Eur Respir J; 2014 Mar 01; 43(3):763-72. PubMed ID: 24114969
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma.
    Allen A, Siederer S, Yang S.
    Int J Clin Pharmacol Ther; 2016 Apr 01; 54(4):269-81. PubMed ID: 26902504
    [Abstract] [Full Text] [Related]

  • 10. A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.
    Kempsford R, Allen A, Kelly K, Saggu P, Crim C.
    Br J Clin Pharmacol; 2014 Mar 01; 77(3):466-79. PubMed ID: 24093504
    [Abstract] [Full Text] [Related]

  • 11. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.
    Lancet Respir Med; 2013 May 01; 1(3):210-23. PubMed ID: 24429127
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug 01; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 13. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.
    Kempsford R, Allen A, Bal J, Rubin D, Tombs L.
    Br J Clin Pharmacol; 2013 Jun 01; 75(6):1478-87. PubMed ID: 23116485
    [Abstract] [Full Text] [Related]

  • 14. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr 01; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 15. Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease.
    Siederer S, Allen A, Yang S.
    Eur J Drug Metab Pharmacokinet; 2016 Dec 01; 41(6):743-758. PubMed ID: 26474864
    [Abstract] [Full Text] [Related]

  • 16. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb 01; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 17. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
    Oliver A, VanBuren S, Allen A, Hamilton M, Tombs L, Inamdar A, Kempsford R.
    Clin Ther; 2014 Jun 01; 36(6):928-939.e1. PubMed ID: 24793536
    [Abstract] [Full Text] [Related]

  • 18. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.
    Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L.
    Clin Respir J; 2013 Oct 01; 7(4):397-406. PubMed ID: 23578031
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma.
    Calzetta L, Rinaldi B, Cazzola M, Matera MG.
    Expert Opin Drug Metab Toxicol; 2016 Jul 01; 12(7):813-22. PubMed ID: 27253498
    [Abstract] [Full Text] [Related]

  • 20. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
    Mehta R, Farrell C, Hayes S, Birk R, Okour M, Lipson DA.
    Clin Pharmacokinet; 2020 Jan 01; 59(1):67-79. PubMed ID: 31321713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.